AstraZeneca PLC

Short Term Long Term Short Term Comparison Long Term Comparison
  • AZN
  • 1d0.45%
  • 1w-0.04%
  • 1m-5.42%
  • 1y37.47%
ATH
  • ATH Price$9,004.00
  • ATH Date2020-05-13
  • % since ATH-5.51%
  • % to ATH5.83%
ATL
  • ATL Price$238.03
  • ATL Date1993-07-21
  • % from ATL3,474.29%
  • Last Low Price$8200
  • Last Low Date2020-06-08
  • % From Last Low3.76%
IPO
  • IPO Price$0.00
  • % Current ROI USDN/A
  • ATH Price$9,004.00
  • % ROI ATH 378,266.88%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="AZN"]

Key Data [addtoany]

Current price $8508
Sector Healthcare
Industry Drug Manufacturers—General
Today's High/Low $8526/$8382
Volume 823,870.00
Previous Close $8470
52 Week High/Low $9537.09/$5871
Market Cap 111,017,197,568.00
P/E Ratio 91.6747
Forward P/E 1 Yr. $26.46
Earnings Per Share(EPS) $0
Annualized Dividend $0.0257
$8508
[addtoany]

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide.
The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca.
The company serves primary care and specialty care physicians through distributors and local representative offices.
It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc.
to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity